Regeneron Pharma (REGN) Posts Q1 Loss of $0.49, Wider than Views
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $827.61 -1.57%
Financial Fact:
Net loss before income tax benefit: 365.88M
Today's EPS Names:
EDXC, BICX, FBPI, More
Financial Fact:
Net loss before income tax benefit: 365.88M
Today's EPS Names:
EDXC, BICX, FBPI, More
Join SI Premium – FREE
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 loss of ($0.49), $0.13 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $112.2 million versus the consensus estimate of $117.02 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
- Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
